Navigation Links
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Date:3/20/2008

otrexate achieved at least a 50% (ACR50) reduction in symptoms compared to 10.8% of patients receiving placebo and methotrexate; ACR70 was achieved in 22% of the treatment group versus 2% in the control group. A rapid decrease in disease activity (DAS28)(2) was seen as early as two weeks in a greater proportion of patients treated with ACTEMRA plus methotrexate, with 27.5% achieving DAS28 less than or equal to 2.6 by 24 weeks.

Additionally, results showed that 80% of patients in the ACTEMRA (8mg/kg) plus methotrexate group responded with moderate to good improvements in RA symptoms, according to the EULAR response criteria(3), compared with 35% for those treated with placebo and methotrexate at 24 weeks. ACTEMRA was generally well tolerated; the most common adverse events reported more frequently in the ACTEMRA arms of the OPTION trial were upper respiratory tract infection, nasopharyngitis and headache.

The OPTION trial also assessed physical function and quality-of-life at baseline and every four weeks thereafter. Patients receiving ACTEMRA achieved significantly greater improvement in areas of fatigue and mental function at 24 weeks, and achieved normal levels of hemoglobin and C-reactive protein (CRP), a marker of inflammation due to RA, compared with patients receiving placebo plus methotrexate.

"We are very encouraged by the findings of the study as they further establish the role of ACTEMRA and its unique blockade of IL-6 receptors as a potential new biologic treatment option for patients with RA," said Lars Birgerson, M.D., Ph.D, Vice President, Global Head Medical Affairs, Roche.

About ACTEMRA(TM) (tocilizumab)

ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody. Studies suggest that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, may reduce inflammation of the joints and relieve certain systemic effects of RA. The extensive clinical
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... N.J. , Aug. 3, 2015  Celsion ... the Company will host a conference call to ... provide an update on its development programs for ... and two newly acquired technology platforms, TheraPlas™ and ... a.m. EDT on Monday, August 10, 2015. To ...
(Date:8/3/2015)... -- Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP ), ... will present live at VirtualInvestorConferences.com on August 6, 2015. ... EDT LINK:    http://tinyurl.com/aug6-pre-imnp This ... are invited to ask the company questions in real-time ... the association,s "virtual trade booth." If attendees are not ...
(Date:8/3/2015)... BOULDER, Colo., Aug. 3, 2015  Encision Inc. (PK:ECIA), ... prevents dangerous stray electrosurgical burns in minimally invasive surgery, ... quarter that ended June 30, 2015. The ... a quarterly net loss of $213 thousand, or $(0.02) ... $2.476 million for a net loss of $202 thousand, ...
Breaking Medicine Technology:Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, ... contract lifecycle management solution, as well as announced the date of its next ... and ease of contract management tasks as well as enhancements to the customer ...
(Date:8/3/2015)... Pass, OR (PRWEB) , ... August 03, 2015 ... ... Northeast California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among ... of California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi ...
(Date:8/3/2015)... ... , ... Illinois Health & Science (IHS) has completed the purchase of IBA ... of IBAM NA’s cyclotron sites and research and development facilities. , “We ... well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and ...
(Date:8/3/2015)... ... , ... Foot and Ankle Specialists of the Mid-Atlantic (FASMA) is ... practice in the Mid-Atlantic region – and the second largest in the United States ... , Dr. Hetal Kathrotiya-Mago is a Maryland native. She grew up in Laurel, Maryland. ...
(Date:8/2/2015)... ... August 03, 2015 , ... Career Step, ... exhibiting at the Association for Healthcare Documentation Integrity’s (AHDI) conference being held in ... for the opportunity the AHDI conference provides us to interact with those in ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2
... , WEDNESDAY, Dec. 8 (HealthDay News) -- A new ... blood to scan the genome of a fetus may offer ... genetic diseases, a new study suggests. Currently, a sample ... amniocentesis or chorionic villus sampling, both of which pose a ...
... HealthDay Reporter , WEDNESDAY, Dec. 8 (HealthDay News) -- Allison Glover ... little more than two months after she gave birth to him ... seven weeks early, on Feb. 23, 2000, but both had relatively ... and living in Stone Mountain, Ga. Garrett seemed the ...
... Patients who have complications after colorectal cancer surgery ... is clearly recommended for their diagnosis, a new study ... In addition, patients with complications were more than ... more than 120 days after diagnosis or two months ...
... Learning to read and write are complex processes, which ... known as dyslexia and dysgraphia. Two new studies, published ... ( http://www.sciencedirect.com/science/journal/00109452 ) provide evidence of this variety, ... account. A group of researchers from the Universities ...
... becoming tastier and more appealing to consumers thanks to new ... forms of fiber, which could be a boon to health, ... of Chemical & Engineering News (C&EN), ACS, weekly newsmagazine. ... plays key roles in human health. Fiber creates a feeling ...
... -- Kidney failure patients who are married are more likely ... or widowers or have never married, finds a new study. ... with end-stage kidney failure. Previous research has shown that males, ... more likely than others to receive kidney transplants in the ...
Cached Medicine News:Health News:Mother Talks of the Anger, Confusion and Grief of a SIDS Death 2Health News:Mother Talks of the Anger, Confusion and Grief of a SIDS Death 3Health News:Surgery complications linked to chemotherapy delay, U-M study finds 2Health News:Widening our perceptions of reading and writing difficulties 2Health News:Marital Status May Affect Kidney Transplant Decision 2
Rad-5v signal extraction pulse oximeter™...
... The WristOx® 3100 is a ... to be worn comfortably on ... monitoring daily activities and for ... of the WristOx is intended ...
... The PulseOx 5500TM is the ... blood oxygen saturation and heart rate ... The PulseOx 5500TM uses SPO Medicals ... device which is more usable for ...
All-in-One Fingertip Oximeter...
Medicine Products: